Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients
Primary Purpose
Asthma
Status
Completed
Phase
Not Applicable
Locations
Thailand
Study Type
Interventional
Intervention
Inhaled Mometasone/formoterol
Inhaled Fluticasone/Salmeterol
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Newly diagnosed asthma, peripheral airway function
Eligibility Criteria
Inclusion Criteria:
- Newly diagnosed asthma according to Global Initiative for Asthma (GINA) guideline 2014 without previous treatment of inhaled corticosteroid and long acting beta agonists
- Patients with asthma symptoms of most days or wake up due to asthma one time per week or more
- Patients with the presence of any risk factors of asthma according to Global Initiative for Asthma (GINA) guideline 2014
- Patients with severe uncontrolled asthma
- Patients with previous asthma exacerbation
- Patients give consent form
Exclusion Criteria:
- Patients with contra-indication for performing spirometry according to American Thoracic Society (ATS) and European Respiratory Society (ERS) statement of standardization for spirometry
- Patients refuse to participate study -
Sites / Locations
- Faculty of Medicine, Ramathibodi Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Inhaled Mometasone/formoterol
Inhaled Fluticasone/Salmeterol
Arm Description
Inhaled Mometasone/Formoterol (100/5 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
Outcomes
Primary Outcome Measures
Peripheral airway function measured by impulse oscillometry
The measuring of airway resistance at 5 and 20 Hz
Secondary Outcome Measures
Peak expiratory flow rate
Peak expiratory flow rate
Forced expiratory volume at 1 second
Forced expiratory volume at 1 second
Forced vital capacity
Forced vital capacity
Forced expiratory flow rate at 25-75% of vital capacity
Forced expiratory flow rate at 25-75% of vital capacity
Asthma control test score
Asthma control test score
Asthma control questionnaire-7 version
Asthma control questionnaire-7 version
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02415179
Brief Title
Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients
Official Title
Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol on Peripheral Airway Function in Asthma Patients
Study Type
Interventional
2. Study Status
Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
May 2015 (undefined)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
February 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mahidol University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to investigate the effectiveness of inhaled mometasone/formoterol versus inhaled fluticasone/salmeterol on peripheral airway function in treatment of asthma.
Detailed Description
Peripheral airway dysfunction is associated with poor asthma outcome including asthma exacerbation and more symptoms. The peripheral or small airway is anatomically defined by airways with 2 mm diameter or less. Several techniques have been used for evaluating peripheral airways such as spirometry, body plethysmography, impulse oscillometry and imaging studies. Since inhaled corticosteroid is corner stone for treatment of asthma, the addition of long acting beta agonist is indicated in severe asthma with poorly controlled disease despite of high dose inhaled corticosteroid.
The inhaled corticosteroid and long acting beta agonists are available for treating asthma. There were different results in comparison studies of different inhaled corticosteroid and long acting beta agonist. These differences are related to type of inhaled formulation, potency of inhaled corticosteroid or dose and outcome measurements. The previous short term studies shown that inhaled budesonide/formoterol is superior to inhaled fluticasone/salmeterol combination for reducing of peripheral airway resistance measured by impulse oscillometry. However, the active drug was delivered by using dry powder inhaler. There is no direct comparison between inhaled mometasone/formoterol and inhaled fluticasone/salmeterol administered using metered dose inhalers. For these reasons, we conduct the open label study comparing the effect of two inhaled corticosteroid and long acting beta agonist in newly diagnosed asthma who are eligible for being treated with such combination therapies.
Eligible patients who have clinically diagnosed asthma requiring treatment with combined inhaled corticosteroid and long acting beta agonist according to Global Initiative for Asthma (GINA) guideline. The patients will be randomized to receive either inhaled mometasone/formoterol (100/5 microgram) 2 puffs twice daily or inhaled fluticasone/salmeterol (125/25 microgram) 2 puffs twice daily administered using metered dose inhalers.
The primary outcome is peripheral airway function measured by airway resistance at 5 and 20 Hz frequency from impulse oscillometry. The secondary outcome are peak expiratory flow rate, forced expiratory flow at 1 second, forced vital capacity, forced expiratory flow at 25-75% of vital capacity (FEF25-75%) measured by spirometry, residual volume per total lung capacity ratio measured by body plethysmography ,asthma control test score and asthma control questionaire-7 version. All outcome are measured at baseline and 6-week post treatments in both arms.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Newly diagnosed asthma, peripheral airway function
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
52 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Inhaled Mometasone/formoterol
Arm Type
Experimental
Arm Description
Inhaled Mometasone/Formoterol (100/5 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
Arm Title
Inhaled Fluticasone/Salmeterol
Arm Type
Active Comparator
Arm Description
Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
Intervention Type
Drug
Intervention Name(s)
Inhaled Mometasone/formoterol
Intervention Description
Inhaled Mometasone/formoterol (100/5 microgram) 2 puffs twice daily via metered dose inhaler for 6 weeks
Intervention Type
Drug
Intervention Name(s)
Inhaled Fluticasone/Salmeterol
Intervention Description
Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
Primary Outcome Measure Information:
Title
Peripheral airway function measured by impulse oscillometry
Description
The measuring of airway resistance at 5 and 20 Hz
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Peak expiratory flow rate
Description
Peak expiratory flow rate
Time Frame
6 weeks
Title
Forced expiratory volume at 1 second
Description
Forced expiratory volume at 1 second
Time Frame
6 weeks
Title
Forced vital capacity
Description
Forced vital capacity
Time Frame
6 weeks
Title
Forced expiratory flow rate at 25-75% of vital capacity
Description
Forced expiratory flow rate at 25-75% of vital capacity
Time Frame
6 weeks
Title
Asthma control test score
Description
Asthma control test score
Time Frame
6 weeks
Title
Asthma control questionnaire-7 version
Description
Asthma control questionnaire-7 version
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Newly diagnosed asthma according to Global Initiative for Asthma (GINA) guideline 2014 without previous treatment of inhaled corticosteroid and long acting beta agonists
Patients with asthma symptoms of most days or wake up due to asthma one time per week or more
Patients with the presence of any risk factors of asthma according to Global Initiative for Asthma (GINA) guideline 2014
Patients with severe uncontrolled asthma
Patients with previous asthma exacerbation
Patients give consent form
Exclusion Criteria:
Patients with contra-indication for performing spirometry according to American Thoracic Society (ATS) and European Respiratory Society (ERS) statement of standardization for spirometry
Patients refuse to participate study -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tananchai Petnak, M.D.
Organizational Affiliation
Pulmonary and critical care, Department of Medicine, Ramathibodi Hospital, Mahidol University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Theerasuk Kawamatawong, M.D.
Organizational Affiliation
Pulmonary and critical care, Department of Medicine, Ramathibodi Hospital, Mahidol University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Prapaporn Pornsuriyasak, M.D.
Organizational Affiliation
Pulmonary and critical care, Department of Medicine, Ramathibodi Hospital, Mahidol University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Viboon Boonsarngsuk, M.D.
Organizational Affiliation
Pulmonary and critical care, Department of Medicine, Ramathibodi Hospital, Mahidol University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Naparat Amornputtisathaporn, M.D.
Organizational Affiliation
Pulmonary and critical care, Department of Medicine, Ramathibodi Hospital, Mahidol University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Faculty of Medicine, Ramathibodi Hospital
City
Bangkok
Country
Thailand
12. IPD Sharing Statement
Citations:
PubMed Identifier
11401872
Citation
Kraft M, Pak J, Martin RJ, Kaminsky D, Irvin CG. Distal lung dysfunction at night in nocturnal asthma. Am J Respir Crit Care Med. 2001 Jun;163(7):1551-6. doi: 10.1164/ajrccm.163.7.2008013.
Results Reference
background
PubMed Identifier
11842317
Citation
Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002 Feb;109(2 Suppl):S447-60. doi: 10.1067/mai.2002.121409.
Results Reference
background
PubMed Identifier
16192448
Citation
Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005 Dec 15;172(12):1497-504. doi: 10.1164/rccm.200410-1414OC. Epub 2005 Sep 28.
Results Reference
background
PubMed Identifier
21828036
Citation
Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C; P04073 Study Investigators. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J. 2012 Feb;39(2):279-89. doi: 10.1183/09031936.00020310. Epub 2011 Aug 4.
Results Reference
background
PubMed Identifier
25194884
Citation
Kirsten AM, Watz H, Brindicci C, Piccinno A, Magnussen H. Effects of beclomethason/formoterol and budesonide/formoterol fixed combinations on lung function and airway inflammation in patients with mild to moderate asthma--an exploratory study. Pulm Pharmacol Ther. 2015 Apr;31:79-84. doi: 10.1016/j.pupt.2014.08.007. Epub 2014 Sep 4.
Results Reference
background
PubMed Identifier
22152089
Citation
Bernstein DI, Hebert J, Cheema A, Murphy KR, Cherrez-Ojeda I, Matiz-Bueno CE, Kuo WL, Nolte H. Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma. Allergy Asthma Clin Immunol. 2011 Dec 7;7(1):21. doi: 10.1186/1710-1492-7-21.
Results Reference
background
PubMed Identifier
21624490
Citation
Hozawa S, Terada M, Hozawa M. Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma. Pulm Pharmacol Ther. 2011 Oct;24(5):571-6. doi: 10.1016/j.pupt.2011.05.004. Epub 2011 May 23.
Results Reference
background
Learn more about this trial
Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients
We'll reach out to this number within 24 hrs